Literature DB >> 12384379

In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Gordon Ramage1, Kacy VandeWalle, Stefano P Bachmann, Brian L Wickes, José L López-Ribot.   

Abstract

We have examined the in vitro activities of fluconazole, amphotericin B, and caspofungin against Candida albicans biofilms by time-kill methodology. Fluconazole was ineffective against biofilms. Killing of biofilm cells was suboptimal at therapeutic concentrations of amphotericin B. Caspofungin displayed the most effective pharmacokinetic properties, with > or =99% killing at physiological concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384379      PMCID: PMC128738          DOI: 10.1128/AAC.46.11.3634-3636.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Intravascular catheter-associated infections.

Authors:  J A Crump; P J Collignon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-01       Impact factor: 3.267

2.  Is there in vivo-in vitro correlation between antifungal susceptibility, species of Candida spp. and clinical outcome?

Authors:  V Krcmery
Journal:  Int J Antimicrob Agents       Date:  2000-12       Impact factor: 5.283

3.  The echinocandins, first novel class of antifungals in two decades: will they live up to their promise?

Authors:  J R Graybill
Journal:  Int J Clin Pract       Date:  2001-11       Impact factor: 2.503

Review 4.  Biofilm formation: a clinically relevant microbiological process.

Authors:  R M Donlan
Journal:  Clin Infect Dis       Date:  2001-09-20       Impact factor: 9.079

Review 5.  Biofilms of Candida albicans and their associated resistance to antifungal agents.

Authors:  G Ramage; B L Wickes; J L Lopez-Ribot
Journal:  Am Clin Lab       Date:  2001-08

6.  Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans.

Authors:  D S Burgess; R W Hastings; K K Summers; T C Hardin; M G Rinaldi
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

7.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

10.  Characteristics of biofilm formation by Candida albicans.

Authors:  G Ramage; K Vandewalle; B L Wickes; J L López-Ribot
Journal:  Rev Iberoam Micol       Date:  2001-12       Impact factor: 1.044

View more
  77 in total

1.  Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.

Authors:  Priya Uppuluri; Anand Srinivasan; Anand Ramasubramanian; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Candida biofilms: an update.

Authors:  Gordon Ramage; Stephen P Saville; Derek P Thomas; José L López-Ribot
Journal:  Eukaryot Cell       Date:  2005-04

3.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

5.  In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms.

Authors:  Semanti Sarkar; Priya Uppuluri; Christopher G Pierce; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 6.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Real-time microscopic observation of Candida biofilm development and effects due to micafungin and fluconazole.

Authors:  Yukihiro Kaneko; Susumu Miyagawa; On Takeda; Masateru Hakariya; Satoru Matsumoto; Hideaki Ohno; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

8.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Penetration of Candida biofilms by antifungal agents.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.